Although several genes are implicated in the pathogenesis of schizophrenia, in animal models for such a severe mental illness only some aspects of the pathology can be represented (endophenotypes). Genetically modified mice are currently being used to obtain or characterize such endophenotypes. Since its cloning and characterization CB1 receptor has increasingly become of significant physiological, pharmacological and clinical interest. Recently, its involvement in schizophrenia has been reported. Among the different approaches employed, gene targeting permits to study the multiple roles of the endocannabinoid system using knockout (-/-) mice represent a powerful model but with some limitations due to compensation. To overcome such a limitation, we have generated an inducible and reversible tet-off dependent tissue-specific CB1-/- mice where the CB1R is re-expressed exclusively in the forebrain at a hypomorphic level due to a mutation (IRh-CB1-/-) only in absence of doxycycline (Dox). In such mice, under Dox+ or vehicle, as well as in wild-type (WT) and CB1-/-, two endophenotypes motor activity (increased in animal models of schizophrenia) and pre-pulse inhibition (PPI) of startle reflex (disrupted in schizophrenia) were analyzed. Both CB1-/- and IRh-CB1-/- showed increased motor activity when compared to WT animals. The PPI response, unaltered in WT and CB1-/- animals, was on the contrary highly and significantly disrupted only in Dox+ IRh-CB1-/- mice. Such a response was easily reverted after either withdrawal from Dox or haloperidol treatment. This is the first Inducible and Reversible CB1-/- mice model to be described in the literature. It is noteworthy that the PPI disruption is not present either in classical full CB1-/- mice or following acute administration of rimonabant. Such a hypomorphic model may provide a new tool for additional in vivo and in vitro studies of the physiological and pathological roles of cannabinoid system in schizophrenia and in other psychiatric disorders.
References
[1]
Parolaro D, Realini N, Vigano D, Guidali C, Rubino T (2010) The endocannabinoid system and psychiatric disorders. Exp Neurol 224: 3–14.
[2]
Papaleo F, Lipska BK, Weinberger DR (2012) Mouse models of genetic effects on cognition: Relevance to schizophrenia. Neuropharmacology. 62: 1204–20.
[3]
Bu？an M, Abel T (2002) The mouse: genetics meets behavior. Nat Rev Genet 3: 114–123.
[4]
Amann LC, Gandal MJ, Halene TB, Ehrlichman RS, White SL, et al. (2010) Mouse behavioral endophenotypes for schizophrenia. Brain Res Bull 83: 147–161.
[5]
Kirby BP, Waddington JL, O’Tuathaigh CM (2010) Advancing a functional genomics for schizophrenia: psychopathological and cognitive phenotypes in mutants with gene disruption. Brain Res Bull 83: 162–176.
[6]
Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, et al. (2010) Cannabinoid receptors and their ligands: beyond CB? and CB?. Pharmacol Rev 62: 588–631.
[7]
Rodríguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, et al. (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcoholism 40: 2–14.
[8]
Pertwee R (2008) Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 13: 147–159.
[9]
Spano MS, Fadda P, Frau R, Fattore L, Fratta W (2010) Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. Eur Neuropsychopharmacol 20: 25–36.
[10]
Ortega-Alvaro A, Aracil-Fernández A, García-Gutiérrez MS, Navarrete F, Manzanares J (2011) Deletion of CB (2) cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology 36: 1489–1504.
[11]
Bossong MG, Niesink RJ (2010) Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. ProgNeurobiol. 92: 370–85.
[12]
Malone DT, Hill MN, Rubino T (2010) Adolescent cannabis use and psychosis:epidemiology and neurodevelopmental models. Br J Pharmacol160: 511–22.
[13]
Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, et al. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 370: 319–328.
[14]
Hamdani N, Tabeze JP, Ramoz N, Ades J, Hamon M, et al. (2008) The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur Neuropsychopharmacol 18: 34–40.
[15]
Leroy S, Griffon N, Bourdel MC, Olié JP, Poirier MF, et al. (2001) Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am J Med Genet 105: 749–752.
[16]
Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, et al. (2002) CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7: 515–518.
[17]
Seifert J, Ossege S, Emrich HM, Schneider U, Stuhrmann M (2007) No association of CNR1 gene variations with susceptibility to schizophrenia. Neurosci Lett 426: 29–33.
[18]
Haller J, Barna I, Barsvari B, Gyimesi Pelczer K, et al. (2009) Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology 204: 607–616.
[19]
Moreira FA, Guimar？es FS (2005) Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol. 512: 199–205.
[20]
Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, et al. (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29: 2108–2114.
[21]
Valverde O, Karsak M, Zimmer A (2005) Analysis of the endocannabinoid system by using CB1cannabinoid receptor knockout mice. Cannabinoids (Pertwee, RG ed), Handbook of experimental pharmacology 168, 120–121, Berlin: Springer-Verlag.
[22]
Steiner H, Bonner TI, Zimmer AM, Kitai ST, Zimmer A (1999) Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. PNAS USA 96: 5787–5790.
[23]
Braff DL (2010) Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. Curr Top Behav Neurosci 4: 349–71.
[24]
Martin RS, Secchi RL, Sung E, Lemaire M, Bonhaus DW, et al. (2003) Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology 165: 128–135.
[25]
Schneider M, Koch M (2002) The cannabinoid agonist WIN 55,212–2 reduces sensorimotor gating and recognition memory in rats. Behav Pharmacol 13: 29–37.
[26]
Bortolato M, Aru GN, Frau R, Orrù M, Luckey GC, et al. (2005) The CB receptor agonist WIN 55,212–2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology 177: 264–271.
[27]
Malone DT, Long LE, Taylor DA (2004) The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice. Pharmacol Biochem Behav. 77: 839–845.
[28]
Nagai H, Egashira N, Sano K, Ogata A, Mizuki A, et al. (2006) Antipsychotics improve Δ9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice. Pharmacol Biochem Behav 84: 330–336.
[29]
Ballmaier M, Bortolato M, Rizzetti C, Zoli M, Gessa G, et al. (2007) Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacol 32: 2098–2107.
[30]
Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, et al. (2010) A behavioral comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 13: 861–876.
[31]
Powell SB, Zhou X, Geyer MA (2009) Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res 204: 282–94.
[32]
Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401–404.
[33]
Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 96: 5780–5785.
[34]
Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, et al. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84–88.
[35]
Azad SC, Kurz J, Marsicano G, Lutz B, Zieglg？nsberger W, et al. (2008) Activation of CB1 specifically located on GABAergic interneurons inhibits LTD in the lateral amygdala. Learn Mem 15: 143–152.
[36]
Mayford M, Wang J, Kandel ER, O’Dell TJ (1995) CaMKII regulates the frequency-response function of hippocampal synapses for the production of both LTD and LTP. Cell 81: 891–904.
[37]
Mansuy IM, Bujard H (2000) Tetracycline-regulated gene expression in the brain. Curr Opin Neurobiol 10: 593–596.
[38]
Sch？nig K, Bujard H (2003) Generating conditional mouse mutants via tetracycline-controlled gene expression. Methods Mol Biol 209: 69–104.
[39]
Nonchev SG, Maconochie MK (2000) Spatial analysis of gene expression. Mouse genetics and transgenics: A practical Approach. (Jackson IJ & Abbott CM eds), pp61–86. Oxford: Oxford UP.
[40]
Castelli MP, Piras AP, Melis T, Succu S, Sanna F, et al. (2007) Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. Neuroscience 147: 197–206.
[41]
Bodor AL, Katona I, Nyíri G, Mackie K, Ledent C, et al. (2005) Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci 25: 6845–56.
[42]
Bortolato M, Frau R, Orrù M, Piras AP, Fà M, et al. (2007) Activation of GABA(B) receptors reverses spontaneous gating deficits in juvenile DBA/2J. Psychopharmacol 194: 361–369.
[43]
Saunders TL (2008) Reporter molecules in genetically engineered mice. Transgenic mouse: Methods and protocols (Hokfer MH and van Deursen J, eds), pp125–136. Totowa: Humana Press.
[44]
Ng PC, Henikoff S (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 31: 3812–3814.
[45]
Egertová M, Elphick MR (2000) Localization of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 422: 159–171.
[46]
Grimsey NL, Narayan PJ, Dragunow M, Glass M (2008) A novel high-throughput assay for the quantitative assessment of receptor trafficking. Clin Exper Pharmacol Physiol 35: 1377–1382.
[47]
Leterrier C, Bonnard D, Carrel D, Rossier J, Lenkei Z (2004) Constitutive endocytic cycle of the CB1 cannabinoid receptor. J Biol Chem 279: 36013–36021.
[48]
El Manira A, Kyriakatos A (2010) The role of endocannabinoid signaling in motor control. Physiology 25: 230–238.
[49]
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530–534.
[50]
Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, et al. (2007) Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol 5: e269.
[51]
H？ring M, Marsicano G, Lutz B, Monory K (2007) Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 146: 1212–1219.
[52]
Sigel E, Baur R, Rácz I, Marazzi J, Smart TG, et al. (2011) The major central endocannabinoid directly acts at GABA(A) receptors. Proc Natl Acad Sci U S A 108: 18150–18155.
[53]
H？ring M, Guggenhuber S, Lutz B (2012) Neuronal populations mediating the effects of endocannabinoids on stress and emotionality. Neuroscience. Available: http://dx.doi.org/10.1016/j.neuroscience？.2011.12.035.
[54]
Chaouloff F, Dubreucq S, Bellocchio L, Marsicano G (2011) Endocannabinoids and motor behavior: CB1 receptors also control running activity. Physiology 26: 76–7.
[55]
Swedlow NR, Weber M, Qu Y, Light GA, Braff DL (2008) realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 199: 331–388.
[56]
Papaleo F, Weinberger DR (2011) Dysbindin and Schizophrenia: it’s dopamine and glutamate all over again. Biol Psychiatry 69: 2–4.
[57]
Karlsgodt KH, Robleto K, Trantham-Davidson H, Jairl C, Cannon TD, et al. (2011) Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance. Biol Psychiatry 69: 28–34.
[58]
Rozenfeld R, Devi LA (2008) Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J 22: 2311–2322.
[59]
Andersson H, D’Antona AM, Kendall DA, Von Heijne G, Chin CN (2003) Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail. Mol Pharmacol 64: 570–577.
[60]
Denzer AJ, Nabholz CE, Spiess M (1995) Transmembrane orientation of signal-anchor proteins is affected by the folding state but not the size of the N-terminal domain. EMBO J 14: 6311–6317.
[61]
Bohn LM (2007) Constitutive trafficking – More than just running in circles? Mol Pharm 71: 957–958.
[62]
Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, et al. (1999) Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283: 655–661.
[63]
Ahn S, Nelson CD, Garrison TR, Miller WE, Lefkowitz RJ (2003) Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc Natl Acad Sci U S A 100: 1740–1744.
[64]
Pettit DA, Harrison MP, Olson JM, Spencer RF, Cabral GA (1998) Immunohistoche-mical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res 51: 391–402.
[65]
Rozenfeld R (2011) Type I cannabinoid receptor trafficking: all roads lead to lysosome traffic. Traffic 12: 12–18.
[66]
Brailoiu GC, Oprea TI, Zhao P, Abood ME, Brailoiu E (2011) Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide. J Biol Chem 286: 29166–291740.
[67]
Giakoumaki SG, Roussos P, Rogdaki M, Karli C, Bitsios P, et al. (2007) Evidence of disrupted prepulse inhibition in unaffected siblings of bipolar disorder patients. Biol Psychiatry 62: 1418–1422.
[68]
Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, et al. (2009) A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 66: 1072–1080.
[69]
Jones CA, Watson DJG, Fone KCF (2011) Animal models of schizophrenia. Themed Issue: Translational Neuropharmacology – Using Appropriate Animal Models to Guide Clinical Drug Development. British Journal of Pharmacology. Available: http://dx.doi.org/10.1111/bph.2011.164.i？ssue-4.
